Impairment of working memory is one of the most important deleterious effects of marijuana intoxication in humans, but its underlying mechanisms are presently unknown. Here, we demonstrate that the impairment of spatial working memory (SWM) and in vivo long-term depression (LTD) of synaptic strength at hippocampal CA3-CA1 synapses, induced by an acute exposure of exogenous cannabinoids, is fully abolished in conditional mutant mice lacking type-1 cannabinoid receptors (CB 1 R) in brain astroglial cells but is conserved in mice lacking CB 1 R in glutamatergic or GABAergic neurons. Blockade of neuronal glutamate N-methyl-D-aspartate receptors (NMDAR) and of synaptic trafficking of glutamate a-amino-3-hydroxy-5-methyl-isoxazole propionic acid receptors (AMPAR) also abolishes cannabinoid effects on SWM and LTD induction and expression. We conclude that the impairment of working memory by marijuana and cannabinoids is due to the activation of astroglial CB 1 R and is associated with astroglia-dependent hippocampal LTD in vivo.
INTRODUCTION
The treatments of pain, nausea, seizures, ischemia, cerebral trauma and tumors in humans and/or animals are some of the potential therapeutic applications of derivatives of the plant Cannabis sativa (marijuana) or synthetic cannabinoids (Lemberger, 1980; Robson, 2001; Brooks, 2002; Carlini, 2004; Hall et al., 2005) . However, the potential therapeutic use of cannabis is limited by important side-effects associated with its use (Pacher et al., 2006) . One of the major side effects of marijuana intoxication is the impairment of working memory in humans (Ranganathan and D'Souza, 2006) and animals (Lichtman and Martin, 1996; Hampson and Deadwyler, 2000; Nava et al., 2001; Varvel and Lichtman, 2002; Fadda et al., 2004; Hill et al., 2004; Wise et al., 2009) , but the cellular mechanisms of this effect are presently not known.
Working memory is the ability to transiently hold and process information for reasoning, comprehension and learning, such as active thinking. Baddeley introduced a multicomponent model of human working memory with a central executive system responsible for information integration and coordination of two subsystems (Baddeley, 2003) . One subsystem, the phonological loop, stores the sound of language while the other subsystem, the visuo-spatial sketch pad, stores visual (e.g., color) and spatial information (i.e., location). This theory suggests a key role of spatial processing in working memory performance. Spatial working memory (SWM) in humans and animals requires online processing of information within many brain regions including the hippocampus (Hassabis et al., 2007; Kesner, 2007) . The hippocampal excitatory CA3-CA1 synapses, which connect glutamatergic axons of CA3 pyramidal neurons, including the ipsilateral Schaffer collaterals and contralateral commissural fibers, with dendrites of CA1 pyramidal neurons (Witter and Amaral, 2004) , have been proposed to play a key role in SWM (Rolls and Kesner, 2006) .
Multiple forms of memory are likely subserved by activity-or experience-dependent long-term potentiation (LTP) and depression (LTD) of synaptic strength (Malenka and Bear, 2004) . Chronic exposure of rats to cannabinoids impairs both LTP induction at CA3-CA1 synapses and hippocampal-dependent SWM (Hill et al., 2004) , suggesting a link between LTP impairment and SWM impairment. This idea is supported by recent data that knockout of the AMPAR GluR1 subunit impairs both LTP induction at CA3-CA1 synapses and SWM (Sanderson et al., 2008) . If LTP at CA3-CA1 synapses indeed contributes to SWM, LTD at these synapses may play a role in SWM impairment, because LTD could counteract LTP at the same synapses (Han et al., 2011) .
Cannabinoid type-1 receptor (CB 1 R), one of the most abundant G protein-coupled receptors in the brain (Herkenham et al., 1990) , is found in both GABAergic and glutamatergic neurons in the hippocampal CA1 region (Herkenham et al., 1990; Kawamura et al., 2006; Marsicano and Lutz, 2006) . Its main neuronal action is to inhibit presynaptic neurotransmitter release (Kano et al., 2009; Marsicano and Lutz, 2006) . Indeed, cannabinoids can depress excitatory transmission at CA3-CA1 synapses in brain slices via activation of CB 1 R (Misner and Sullivan, 1999; Hajos et al., 2001; Kawamura et al., 2006; Marsicano and Lutz, 2006; Takahashi and Castillo, 2006; Bajo et al., 2009; Serpa et al., 2009; Hoffman et al., 2010) . Thus, cannabinoid-induced decrease of excitatory transmission might be related to SWM impairment. It is entirely unknown, however, whether cannabinoids are able to induce LTD at CA3-CA1 synapses in living animals and whether such in vivo LTD might contribute to SWM impairment induced by exogenous cannabinoids. In addition to the presence in neurons, CB 1 R is also found in hippocampal astroglial cells and its activation, by stimulating Ca 2+ -dependent release of glutamate, potentiates synaptic transmission at CA3-CA1 synapses in brain slices (Navarrete and Araque, 2010) . However, the roles of astroglial CB 1 R in the modulation of behavior and synaptic plasticity in living animals are not known.
In this study, we employed conditional mutagenesis, in vivo electrophysiology and behavioral tests to study the mechanism underlying the effect of cannabinoids on hippocampal-dependent SWM. Surprisingly, we found that activation of astroglial CB 1 R, but not neuronal CB 1 R, by exogenous cannabinoids mediates SWM impairment and LTD induction at CA3-CA1 synapses in vivo. Our data reveal an unanticipated hippocampal pathway linking astroglial activity, synaptic plasticity and memory processing, and define the specific mechanisms likely underlying cannabinoid-induced impairment of SWM in living animals.
RESULTS

Cannabinoids Induce In Vivo LTD at CA3-CA1 Synapses
In vivo recordings of field excitatory postsynaptic potentials (fEPSP) from CA3-CA1 synapses in anesthetized rats revealed that an i.p. injection of HU210 (0.05 or 0.1 mg/kg), a potent synthetic cannabinoid, or D 9 -tetrahydrocannabinol (THC, 5 mg/kg), the major psychoactive ingredient of marijuana, decreased fEPSP amplitude to approximately 40% of the baseline levels ( Figures 1A and 1G ). Similar results were obtained after an intra-CA1 infusion of HU210 (Figures S1A and S1C). In studies hereafter, animals received an i.p. injection of 0.05 mg/kg of HU210 or 5 mg/kg of THC if not otherwise stated.
Cannabinoid-induced depression of synaptic transmission at CA3-CA1 synapses in brain slices is not defined as LTD, because it is fully reversed by application of CB 1 R antagonists 10 min after cannabinoid application (Chevaleyre et al., 2006; Hajos et al., 2001; Kawamura et al., 2006) . This indicates the requirement of a continuous activation of CB 1 R for cannabinoid depression of transmission at CA3-CA1 synapses, a characteristic of transient synaptic depression but not of LTD (Chevaleyre et al., 2006) . However, we observed that the decreased EPSP amplitude was blocked by injection of the selective CB 1 R antagonist AM281 (3 mg/kg, i.p.) (Cui et al., 2001 ) 10 min before, but not 10 min after HU210 administration ( Figures 1B and 1G ), thus indicating LTD induction by cannabinoid exposure in vivo (hereafter referred to as CB-LTD). This idea is further supported by two lines of evidence. First, while synaptic transmission depression can be transient (in min) or long-lasting (i.e., LTD lasting > 24 h), a HU210 injection (0.1 mg/kg, i.p.) induced CB-LTD at CA3-CA1 synapses for > 24 hr in freely moving rats (Figures 1E and 1G) , at a time where the acute effects of the drug should be decreased. Second, while the maintenance of late-phase LTD, but not early-phase LTD or transient synaptic transmission depression, requires new protein synthesis (Kelleher et al., 2004) , administration of inhibitors of protein translation (anisomycin, 18 mg/kg, i.p.) (Puighermanal et al., 2009) or RNA transcription (actinomycin-D, 72 mg/12 ml, i.c.v.) (Manahan-Vaughan et al., 2000) 2 hr before HU210 injection selectively reversed the late-phase expression of CB-LTD ( Figures 1C and 1G) .
To identify if CB 1 R expressed in the CA1 area contributes to CB-LTD at CA3-CA1 synapses, we applied adenoviral vectors-containing shRNA against CB 1 R into the CA1 region 4 days prior to HU210 injection. shRNA CB 1 R specifically knocked down CA1 expression of CB 1 R ( Figure 1F ) and suppressed CB-LTD at CA3-CA1 synapses ( Figures 1D and 1G) . Interestingly, the cannabinoid effect seems to be specific for the CA3-CA1 pathway, because systemic HU210 did not induce CB-LTD at synapses of the perforant path onto dentate gyrus neurons ( Figures S1B and S1C ). Thus, in vivo cannabinoid exposure induces an in vivo LTD at CA3-CA1 synapses.
Neuronal CB 1 R Is Dispensable for CB-LTD at CA3-CA1 Synapses Glutamatergic presynaptic membranes of CA3-CA1 synapses contain CB 1 R (Kawamura et al., 2006) . To test whether CB-LTD depends on ''glutamatergic'' CB 1 R, we examined mutant mice carrying a selective deletion of the CB 1 R gene in cortical and hippocampal glutamatergic principal neurons (Glu-CB 1 R-KO) (Monory et al., 2006; Bellocchio et al., 2010) . Surprisingly, THC induced a CB-LTD at CA3-CA1 synapses that was indistinguishable between wild-type mice and Glu-CB 1 R-KO littermates (Figures 2A and 2C ). We then determined the induction of CB-LTD in mutant mice carrying a selective deletion of the CB 1 R gene in brain GABAergic neurons (GABA-CB 1 R-KO), including CA1 GABAergic neurons (Monory et al., 2006; Bellocchio et al., 2010) . Again, THC induced a CB-LTD at CA3-CA1 synapses that was indistinguishable between wild-type mice and GABA-CB 1 R-KO littermates (Figures 2A and  2C ). Thus, CB 1 R expressed in glutamatergic or GABAergic neurons does not participate in this in vivo form of CB-LTD in the hippocampal CA1 region.
Astroglial CB 1 R Mediates CB-LTD at CA3-CA1 Synapses CB 1 R is also functionally expressed in CA1 astrocytes (Navarrete and Araque, 2008) . Therefore, astroglial CB 1 R might play a role in CB-LTD at CA3-CA1 synapses. To directly address this issue, we generated tamoxifen-inducible conditional mutant mice specifically lacking CB 1 R expression in astrocytes. ''Floxed'' CB 1 R mutant mice (Marsicano et al., 2003) were crossed with transgenic mice expressing the inducible version of the Cre recombinase CreERT2 under the control of the promoter of the human glial fibrillary acidic protein (GFAP-CreERT2 mice, Hirrlinger et al., 2006) to eventually obtain the GFAP-CB 1 R-KO mouse line. As compared to tamoxifen-treated wild-type littermate controls (GFAP-CB 1 R-WT), GFAP-CB 1 R-KO mice displayed a 79% reduction (p < 0.01) in the number of CA1 astrocytes labeled with a CB 1 R antibody ( Figures 2D and 2F ), whereas only background levels were observed in constitutive CB 1 R-KO mice (Figures 2E and 2G) . Conversely, no difference (p = 0.2293) was observed between GFAP-CB 1 R-WT and GFAP-CB 1 R-KO mice in the number of CB 1 R-labeled CA1 neuronal axons/terminals ( Figures 2D and 2F ). THC elicited CB-LTD at CA3-CA1 synapses in tamoxifen-treated wild-type mice but not in GFAP-CB 1 R-KO mutant littermates (Figures 2B and 2C) . Therefore, cannabinoid exposure in vivo elicits CB-LTD at CA3-CA1 synapses through CB 1 R expressed in astroglial cells. 
Mechanisms of CB-LTD at CA3-CA1 Synapses
Cannabinoids are able to activate hippocampal astroglial CB 1 R to increase extracellular glutamate levels (Navarrete and Araque, 2008) . If a similar mechanism is involved in CB-LTD, LTD should be induced by the glutamate-uptake inhibitor DL-threo-b-benzyloxyaspartate (TBOA). Indeed, an i.c.v. injection of TBOA (10 nmol) (Wong et al., 2007) induced in vivo LTD at CA3-CA1 synapses ( Figures 3A and 3F ). If increased extracellular levels of glutamate induce LTD at CA3-CA1 synapse, postsynaptic metabotropic glutamate receptor (mGluR) may be responsible for this LTD induction, because postsynaptic mGluR activation produces LTD (Chevaleyre et al., 2006; Lovinger, 2008) . However, the selective group I/group II mGluR antagonist ethyl-4-carboxyphenylglycine (E4CPG, 35 nM/ 3.5 ml, i.c.v.) completely blocked in vivo LTD induced by the group I mGluR agonist dihydroxyphenylglycine (DHPG, 100 nM/5 ml, i.c.v.), but did not alter CB-LTD ( Figures 3B, 3C , and 3F). Surprisingly, CB-LTD was fully blocked by the selective NMDAR antagonist AP-5 (50 mM, intra-CA1 iontophoretic ejection at À20 nA for 10 min) (Maalouf et al., 1998) (Figures 3D and 3F) , and by the NR2B-preferring NMDAR antagonists Ro25-6981 (6 mg/kg, i.p.) (Fox et al., 2006) and ifenprodil (5 mg/kg, i.p.) (Higgins et al., 2005) (Figures 3E and 3F) . However, the NR2A-preferring NMDAR antagonist NVP-AAM077 (1.2 mg/kg, i.p.) (Fox et al., 2006) did not alter CB-LTD in the same conditions ( Figures 3E and 3F) . Thus, in vivo cannabinoid exposure induces CB-LTD at CA3-CA1 synapses via activation of NR2B-containing NMDAR.
The expression of NMDAR-mediated LTD requires facilitated endocytosis of postsynaptic AMPAR (Collingridge et al., 2010) . AMPAR in CA1 pyramidal cells consists of 81% of GluR1/ GluR2 at synaptic membranes (Lu et al., 2009 ). The surface levels of GluR1/GluR2 in synaptosomes isolated from the CA1 region significantly decreased after HU210 injection ( Figure 4A ), suggesting endocytosis of AMPAR in postsynaptic CA1 pyramidal cells following cannabinoid exposure in vivo. The administration of the brain-penetrating version of a peptide able to block GluR2 endocytosis (''Tat-GluR2'' peptide, 1.5 mmol/kg, i.p.), but not of its scrambled analog (Tat-GluR2S) (Brebner et al., 2005; Wong et al., 2007; Collingridge et al., 2010) , specifically blocked both HU210-induced GluR1/GluR2 endocytosis ( Figure 4B ) in the CA1 and CB-LTD (Figures 4C and 4D ). Tat-GluR2 (1.5 mmol/kg, i.p.) did not significantly change the fEPSP amplitude at CA3-CA1 synapses for 4 hr after injection ( Figures 4D and  4E) . Altogether, these data strongly suggest that postsynaptic endocytosis of GluR1/GluR2 mediates the expression of CB-LTD at CA3-CA1 synapses.
Cannabinoid Impairment of Working Memory Shares the Same Mechanisms of CB-LTD CB-LTD is characterized by (1) activation of astroglial CB 1 R, (2) activation of NMDAR, and (3) internalization of AMPAR. These mechanisms were assessed in different behavioral models of cannabinoid impairment of spatial working memory (SWM).
The role of astroglial CB 1 R in cannabinoid impairment of SWM was assessed by examining SWM performance of tamoxifen-treated GFAP-CB 1 R-WT and GFAP-CB 1 R-KO littermates with a delayed-matching-to place (DMTP) version of the Morris water maze test (Steele and Morris, 1999) . No significant differences were observed between wild-type and mutant littermates during training ( Figure S2A ). In agreement with a previous study (Varvel and Lichtman, 2002) , THC impaired SWM performance in GFAP-CB 1 R-WT mice, as evidenced by a significant decrease of both latency saving ratios ( Figure 5A ) and path saving ratios ( Figure 5B ). In contrast, THC did not produce significant effects on GFAP-CB 1 R-KO littermates ( Figures 5A and 5B) . While Glu-CB 1 R-KO littermates showed a significant impairment of the acquisition of SWM ( Figure S2B ) and subsequent poor performance of SWM in comparison with wild-type mice ( Figures 5C and 5D ), THC impaired SWM performance ( Figure 5C ). Both GABA-CB 1 R-KO littermates and control wild-type mice showed similar acquisition of SWM ( Figure S2B ), and THC impaired SWM performance ( Figures  5C and 5D ). THC treatment did not alter swim speed of GFAP-CB 1 R-WT and GFAP-CB 1 R-KO mice ( Figure S2C ), but slightly decreased this parameter in Glu-and GABA-CB 1 R-KO mice and WT littermates ( Figure S2D ). However, this slight effect was equal for all genotypes ( Figure S2D ) and was equally distributed among different trials (data not shown), thereby excluding its involvement in the altered SWM performance of the mice. Thus, CB 1 R in glutamatergic neurons, but not CB 1 R in GABAergic neurons or astroglial cells, is necessary for mice to acquire SWM. Notably, however, astroglial CB 1 R, but not glutamatergic or GABAergic neuronal CB 1 R, is necessary to produce the detrimental effects of THC on SWM.
To test if NMDAR activation plays a role in cannabinoid impairment of SWM, rats were tested in a T-maze using a delayed nonmatching to sample protocol (DNMTST) (Kelsey and Vargas, 1993) . After 6 daily training sessions to ensure that the task was mastered (>80% correct choices, Figure S3A ), rats received 2 daily test sessions 30 min after injection of HU210 or vehicle. Ten min before HU210 injection, rats were pretreated with Ro25-6981 or ifenprodil, two NR2B-preferring NMDAR antagonists, or NVP-AAM077, a NR2A-prefering NMDAR antagonist. The results show that NR2B-but not NR2A-preferring NMDAR antagonists abrogated HU210-induced impairment of SWM performance ( Figure 6A ). Thus, activation of NR2B-containing NMDAR is necessary for the cannabinoid-induced impairment of SWM.
The effects of the blockade of AMPAR internalization on cannabinoid-induced SWM impairment was also tested in the DNMTST paradigm. After 6 daily training sessions ( Figure S3B ), rats received Tat-GluR2 or Tat-GluR2S (1.5 mmol/kg, i.p.) (Brebner et al., 2005; Wong et al., 2007) 2 hr before HU210 injection on each of the two testing days. Tat-GluR2, but not Tat-GluR2S, abolished HU210 impairment of SWM performance ( Figure 6B ). To determine the specific role of the CA1 region, after 6 daily training sessions ( Figure S3C ), Tat-GluR2 or Tat-GluR2S was infused bilaterally within the dorsal CA1 region (15 pmol/per injection) (Brebner et al., 2005; Wong et al., 2007) (Figure 6C ) 60 min before each HU210 injection on each testing day. Intra-CA1 infusion of Tat-GluR2, but not Tat-GluR2S, blocked HU210 impairment of SWM performance ( Figure 6D ). Neither systemic nor intra-CA1 administration of Tat-GluR2 significantly affected basal locomotor activity, anxiety level or motor balance ( Figures  S4A-S4E) . Thus, AMPAR internalization in the CA1 hippocampal region is necessary for cannabinoid-induced alteration of SWM.
If intra-CA1 infusion of HU210 is able to induce CB-LTD at CA3-CA1 synapses ( Figures S1A and S1C) , a bilateral intra-CA1 infusion of HU210 should impair SWM. As expected, after six daily training sessions ( Figure S3D ), HU210 (0.1 mg/ 0.5 ml/side) impaired rat SWM performance ( Figure 6E ).
Finally, we tested if the results obtained with the DNMTST paradigm were reproducible with the DMTP water maze paradigm. One day after five daily training sessions to establish the baseline levels of SWM ( Figure S5A ), rats received a test session of four trials. HU210 treatment before the test session impaired SWM performance, which was blocked by pretreatment with Ro25-6981 or Tat-GluR2 (Figures 5E and 5F ). Neither Ro25-6981 nor Tat-GluR2 administration alone significantly changed saving ratios ( Figures 5E and 5F ), suggesting that neither NR2B-preferring NMDAR antagonists nor Tat-GluR2 interferes with basal SWM performance. Swim speeds during the SWM task were not influenced by different treatments ( Figure S5B ). Thus, cannabinoid administration alters SWM performance in different behavioral tasks through the same mechanisms.
Altogether, these data show that the same mechanisms underlying CB-LTD at hippocampal CA3-CA1 synapses (activation of astroglial CB 1 R, activation of NMDAR and removal of AMPAR from the synaptic surface) also mediate cannabinoidinduced alterations of hippocampal-dependent SWM.
DISCUSSION
This study shows that one of the most common effects of cannabinoid intoxication in humans and animals, the impairment of SWM, is due to activation of astroglial CB 1 R. Furthermore, a novel form of cannabinoid-induced long-term synaptic plasticity in the hippocampus appears to mechanistically underlie this effect of cannabinoids in vivo. Our results are consistent with a scenario (Figure 7) , in which cannabinoid exposure in vivo activates astroglial CB 1 R to increase ambient glutamate, which in turn activates NR2B-containing NMDAR to trigger AMPAR internalization at CA3-CA1 synapses. These events ultimately induce CB-LTD at these synapses, altering the function of hippocampal circuits that likely become unable to process SWM (Figure 7 ).
Early studies demonstrate that CB 1 R is expressed at high levels by neurons throughout the whole brain (Herkenham et al., 1990; Matsuda et al., 1993; Tsou et al., 1998) . More recent studies show that CB 1 R is more abundant in GABAergic interneurons than in glutamatergic principal neurons (Kawamura et al., 2006) . In the hippocampal CA1 area, CB 1 R density on GABAergic presynaptic membranes is at least 10-20 times higher than that on glutamatergic presynaptic membranes (Kawamura et al., 2006; Bellocchio et al., 2010) . Cannabinoid depression of in vitro excitatory or inhibitory synaptic transmission has been consistently shown to require CB 1 R in either glutamatergic or GABAergic presynaptic terminals, respectively (Misner and Sullivan, 1999; Chevaleyre et al., 2006; Kawamura Takahashi and Castillo, 2006; Araque, 2008, 2010; Bajo et al., 2009) . Indeed, cannabinoids fail to reduce excitatory or inhibitory synaptic transmission in hippocampal slices of conditional mutant mice lacking CB 1 R expression in either glutamatergic or GABAergic hippocampal neurons, respectively (Domenici et al., 2006; Monory et al., 2006) . Unexpectedly, we observed here that in vivo exposure to exogenous cannabinoids induced full CB-LTD at excitatory CA3-CA1 synapses in both wild-type mice and mutant littermates lacking CB 1 R in either CA1 glutamatergic or GABAergic neurons. These data do not support an involvement of glutamatergic or GABAergic CB 1 R in in vivo CB-LTD at CA3-CA1 synapses.
The presence of CB 1 R has also been suggested in brain astrocytes (Moldrich and Wenger, 2000; Rodriguez et al., 2001; Salio et al., 2002) , but the extremely low levels of CB 1 R expression in this cell population did not allow reaching the same conclusive evidence of functional data Araque, 2008, 2010) . The use of double immunostaining applied to wild-type and conditional or constitutive CB 1 R mutant mice allowed us to provide conclusive electron microscopic evidence that CB 1 R is expressed and quantifiable in hippocampal astrocytes. We have further showed here that in vivo CB-LTD at CA3-CA1 synapses was not detectable in tamoxifen-inducible conditional mutant mice specifically lacking CB 1 R expression in astrocytes (i.e., GFAP-CB 1 R-KO littermates). Our results strongly suggest a requirement of astroglial CB 1 R for CB-LTD at CA3-CA1 synapses in living animals.
However, we also found that THC exposure in vivo did not significantly alter basal synaptic transmission in GFAP-CB 1 R-KO littermates. These data, together with the finding that the density of presynaptic CB 1 R at CA3-CA1 synapses is just above the background levels (Kawamura et al., 2006) , suggest a negligible role of presynaptic CB 1 R in excitatory transmission in vivo at CA3-CA1 synapses in response to exogenous cannabinoid exposure. Thus, in vitro cannabinoid application decreases excitatory synaptic transmission at CA3-CA1 synapses via activation of ''glutamatergic'' CB 1 R, whereas in vivo cannabinoid administration induces CB-LTD via astroglial CB 1 R without significant effects on presynaptic CB 1 R. The exact reason for this apparent mechanistic discrepancy between in vitro and in vivo effects of cannabinoids on synaptic transmission and plasticity is not known. Nevertheless, it is important to note that intact astroglial networks play prominent roles in brain functioning (Giaume et al., 2010) . Indeed, astrocytes are more associated in networks than neurons due to the presence of high levels of gap junctions and direct intercellullar communications (Giaume et al., 2010) . It is therefore possible that the unavoidable disruption of these networks by slicing procedures might alter the impact of astroglial CB 1 R signaling in vitro. Meanwhile, slicing procedures might also upregulate the number or function of presynaptic CB 1 R, leading to a decrease of glutamatergic transmission upon its activation by exogenous cannabinoids. This idea is supported by the evidence that although CB 1 R density is at least 10-20 times higher on inhibitory than excitatory terminals in the CA1 region (Kawamura et al., 2006; Bellocchio et al., 2010) , application of a saturating concentration of WIN22,212-2 (2 mM) to hippocampal slices produced similar depression ($50%) of EPSC (Kawamura et al., 2006) and IPSC (Hajos and Freund, 2002) in the CA1 area. Because brain slice preparations are extensively used for studying alterations of synaptic strength following in vitro application of other drugs of abuse, it is worthwhile to explore whether astrocytes play a key role in the in vivo effects of these drugs of abuse that are different from their in vitro effects.
Recent studies with brain slices show that endocannabinoids activate CA1 astroglial CB 1 R to increase extracellular glutamate levels, which in turn activate presynaptic mGluR to induce LTP at CA3-CA1 synapses Araque, 2008, 2010) . However, we show here that cannabinoids activate astroglial cells to induce in vivo LTD at CA3-CA1 synapses. It is currently unknown why activation of astroglial CB 1 R by in vitro endocannabinoid and in vivo cannabinoid induces, respectively, in vitro LTP and in vivo LTD at CA3-CA1 synapses. It is possible that activation of astroglial CB 1 R in brain slices with disrupted astroglial networks might produce lower levels of interstitial glutamate than those produced in living animals with intact astroglial networks, which then activate presynaptic mGluR in vitro and Figures 2D-2G ) and presynaptic membranes with 10-to 20-fold of CB 1 R density in GABAergic membranes than glutamatergic membranes (Kawamura et al., 2006) . GABAergic and glutamatergic terminals containing CB 1 R synapse with dendrites and spines of CA1 pyramidal cells, respectively (Kawamura et al., 2006) . In vitro activation of presynaptic CB 1 R by cannabinoids reduces the release of glutamate and GABA from glutamatergic and GABAergic membranes, respectively. However, cannabinoid exposure in vivo sequentially activates astroglial CB 1 R and postsynaptic NR2B-containing NMDAR, which elicits AMPAR endocytosis-mediated expression of in vivo LTD at CA3-CA1 synapses, resulting in working memory impairment.
postsynaptic NMDAR in vivo, respectively, to induce in vitro LTP and in vivo LTD at CA3-CA1 synapses.
This study confirmed the consistent finding that HU210 and THC impair SWM in rodents (Lichtman and Martin, 1996; Hampson and Deadwyler, 2000; Nava et al., 2001; Varvel and Lichtman, 2002; Fadda et al., 2004; Hill et al., 2004; Wise et al., 2009) . Although a recent study claimed the inability of systemic HU210 injection to impair SWM tested with the DMTP water maze paradigm (Robinson et al., 2007) , this study failed to use the 'saving ratio' analysis as we and others (Varvel and Lichtman, 2002) have successfully used to identify the detrimental effects of HU210 and THC on rodent SWM performance.
While glutamatergic axonal CB 1 R is in part responsible for cannabinoid-elicited locomotor suppression, catalepsy and hypothermia (Monory et al., 2007) , hippocampal GABAergic axonal CB 1 R likely plays a key role in cannabinoid impairment of long-term memory (Puighermanal et al., 2009) . Our data using GABA-CB 1 R-KO mice clearly show that ''GABAergic'' CB 1 R is fully dispensable both for basal performance of the SWM task and, most importantly in this context, for the acute effect of exogenous cannabinoids. By showing that Glu-CB 1 R-KO mice are impaired in basal performance of the SWM task, our data suggest that CB 1 R expressed in cortical glutamatergic neurons participates in the endogenous control of SWM. This control might be exerted acutely by endogenous mobilization of endocannabinoids during the task or can also be due to developmental effects of CB 1 R deletion in this cell population (Mulder et al., 2008) . However, exogenous THC treatment of Glu-CB 1 R-KO mice is still able to further reduce their poor performance, strongly suggesting the dispensable role of ''glutamatergic'' CB 1 R in the acute effects of exogenous cannabinoids on SWM performance.
Conversely, by showing that GFAP-CB 1 R-KO mice display normal learning of SWM, but totally fail to respond to THC, the present study provides striking evidence for the necessary role of astroglial CB 1 R in SWM impairment induced by exogenous cannabinoids.
Cannabinoid-induced LTD and impairment of SWM share not only the dependency on astroglial CB 1 R but also a whole series of well-defined molecular mechanisms. Thus, the pharmacological blockade of NR2B-containing NMDAR, but not NR2A-containing NMDAR, prevented both CB-LTD at CA3-CA1 synapses and cannabinoid impairment of SWM. Moreover, the Tat-GluR2 peptide can selectively block the facilitated endocytosis of AMPAR (Collingridge et al., 2010) , the final step of the expression of NMDAR-dependent LTD (Collingridge et al., 2010) , without significant effects on LTP induction or basal synaptic transmission (Collingridge et al., 2010) . Both systemic and intra-CA1 application of the Tat-GluR2 peptide not only disrupted the expression of CB-LTD at CA3-CA1 synapses but also cannabinoid impairment of SWM, as assessed with both the DMTP version of the Morris water maze test and the DNMTS T-maze test.
Collectively, at least three key molecular mechanisms are shared by CB-LTD and cannabinoid-induced impairment of SWM: (1) activation of astroglial CB 1 R by the exogenous cannabinoid; (2) increase of local glutamate and activation of NR2B-containing NMDAR; (3) endocytosis of AMPAR (Figure 7 ). These findings strongly suggest a causative role of CB-LTD at CA3-CA1 synapses in cannabinoid-induced impairment of SWM and reveal novel mechanistic views of the role of astrocytes in learning and memory processes and of the memory-disruptive effects of marijuana intoxication.
EXPERIMENTAL PROCEDURES
Generation of Mutant Mice
Constitutive CB 1 R-KO mice and conditional Glu-CB 1 R-KO and GABA-CB 1 R-KO mice were generated and genotyped as described (Marsicano et al., 2002; Monory et al., 2006) . GFAP-CB 1 R-KO mice were generated using the Cre/loxP system. Mice carrying the ''floxed'' CB 1 R gene (CB 1 f/f ) (Marsicano et al., 2003) were crossed with GFAP-CreERT2 mice (Hirrlinger et al., 2006) , using a threestep backcrossing procedure to obtain CB 1 R f/f;GFAP-CreERT2 and CB 1 R f/f littermates, called GFAP-CB 1 R-KO and GFAP-CB 1 R-WT, respectively.
Immunohistochemistry for Electron Microscopy
Animals were transcardially fixed with 0.1% glutaraldehyde, 4% formaldehyde and 0.2% picric acid or with 2% formaldehyde and 8% picric acid. Hippocampal vibrosections were cut for double preembedding staining of CB 1 R and GFAP with silver-intensified immunogold method and immunoperoxidase method. Tissue preparations were photographed for quantification of positive immunoreactive profiles. Detailed procedures are described in the extended methods in the SOMs.
Adenovirus Preparation and Administration
Recombinant adenoviruses were prepared as described (Liu et al., 2010) . After intra-CA1 infusion of adenoviral vectors (10 10 plaque-forming units/ml/injection), the CA1 area surrounding the injection tract was dissected 4 days later for quantification of CB 1 R protein with procedures as described (Ji et al., 2006; Liu et al., 2010) .
Synaptosomal Surface AMPAR Measurement
Biotinylation experiments for the CA1 area on hippocampal slices were performed as described (Kim et al., 2007) . Protein fractions were transferred onto nitrocellulose membranes, which were probed with primary antibodies to GluR1 (1:250, Millipore, Billerica, MA) or GluR2 (1:500, Millipore, Billerica, MA) overnight at 4 C. Bands were analyzed by densitometry, and receptor ratios for AMPAR subunits were determined by dividing the surface intensity by the total intensity.
Electrophysiology Analysis
Under anesthesia, rats or mice received implantation of stimulating and recording electrodes into the CA1 region. fEPSPs were evoked by applying single pulses of stimulation at 0.067 Hz. Stimulus pulse intensities were 20-60 nA with a duration of 500 ms. Spike2 software was utilized to record data. Procedures for fEPSP recordings from freely moving rats were generally similar to those from anaesthetized rats with the exception of allowing rats to recover for 2 weeks after surgery for electrode implantation. Detailed procedures are described in the extended methods in the SOMs.
Behavioral Tests
Water Maze Test Mice were tested in a DMTP version of the Morris water maze paradigm (Steele and Morris, 1999) . Briefly, after a habituation session of 3 trials without spatial cues, mice received daily training sessions of 4 trials each with the maximal escape latency of 60 s, and 30 min before each of the sessions 6 through 12 and before the 13th session, mice were treated with vehicle and THC (5 mg/kg, i.p.), respectively. Performances of individual SWMs were calculated using the ''saving ratio'' procedure (Varvel and Lichtman, 2002) 
